Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 72 49 55 3 3 14 69
Whooping Cough 12 72 49 55 40 3 41
Bordetella Infections 41 69
Whooping Cough Due to Unspecified Organism 69
Bordetella Pertussis Infection 49
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

55
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
SNOMED-CT 64 26484003
Orphanet 55 ORPHA1489
MESH via Orphanet 42 D014917
UMLS via Orphanet 70 C0043167 C0043168
ICD10 via Orphanet 33 A37.0 A37.1 A37.8 more

Summaries for Pertussis

MedlinePlus : 40 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to laryngitis and cytomegalovirus infection, and has symptoms including snoring, pruritus and fever. An important gene associated with Pertussis is GNA14 (G Protein Subunit Alpha 14), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Montelukast and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A commensal bacterial infectious disease that results_in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

Wikipedia : 72 Pertussis (also known as whooping cough or 100-day cough) is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 laryngitis 29.9 IL1B IL6 TNF
2 cytomegalovirus infection 29.8 IL10 IL6 TNF
3 pneumonia 29.8 IL10 IL1B IL6 TLR4 TNF
4 q fever 29.6 IL10 IL1B TLR4 TNF
5 transverse myelitis 29.6 IL10 IL6 TNF
6 meningitis 29.6 IL10 IL1B IL6 TNF
7 perinatal necrotizing enterocolitis 29.5 IL1B IL6 TLR4 TNF
8 chorioamnionitis 29.5 IL1B IL6 TLR4 TNF
9 brucellosis 29.5 IL10 IL6 TLR4 TNF
10 bronchiolitis 29.5 IL10 IL6 TLR4 TNF
11 contact dermatitis 29.4 IL10 IL1B IL6 TNF
12 human immunodeficiency virus type 1 29.4 IL10 IL6 MAPK1 MAPK10 TNF
13 colitis 29.2 IL10 IL1B IL6 TLR4 TNF
14 sudden infant death syndrome 29.2 IL10 IL1B IL6 TNF
15 monocytic leukemia 29.1 IL1B IL6 ITGAM JUN TNF
16 peritonitis 29.0 IL10 IL1B IL6 ITGAM TNF
17 inflammatory bowel disease 28.8 IL10 IL1B IL6 JUN TLR4 TNF
18 myocardial infarction 28.7 IL10 IL1B IL6 ITGAM TLR4 TNF
19 diphtheria 11.5
20 bordetella parapertussis whooping cough 10.9
21 tetanus 10.8
22 campylobacteriosis 10.5 IL1B JUN TLR4
23 punctate inner choroidopathy 10.5 IL10 TNF
24 influenza 10.5
25 polyposis, gastric 10.5 IL1B TNF
26 prosthetic joint infection 10.5 IL1B TLR4
27 aging 10.4
28 tropical endomyocardial fibrosis 10.4 IL10 TNF
29 salmonellosis 10.4 IL1B JUN TLR4
30 haemophilus influenzae 10.4
31 middle ear disease 10.4 IL1B TLR4 TNF
32 phakomatosis cesioflammea 10.4 GNA11 GNAQ
33 scorpion envenomation 10.4 IL6 TNF
34 endometrial disease 10.4 IL1B IL6 TLR4
35 cysticercosis 10.4 IL1B IL6 TLR4
36 neutrophil migration 10.4 ITGAM ITGB2 MAPK1
37 penicilliosis 10.4 ITGAM TLR4 TNF
38 photokeratitis 10.3 FOS IL6 JUN
39 hepatitis 10.3
40 systemic onset juvenile idiopathic arthritis 10.3 IL1B TNF
41 anterior uveitis 10.3 IL6 TLR4 TNF
42 hepatitis b 10.3
43 recurrent corneal erosion 10.3 IL1B IL6
44 aseptic meningitis 10.3 IL10 IL1B TNF
45 granulocytopenia 10.3 ITGAM ITGB2 TNF
46 funisitis 10.3 IL10 IL1B IL6
47 cutaneous leishmaniasis 10.3 IL10 TLR4 TNF
48 ileitis 10.3 IL6 TLR4 TNF
49 poliomyelitis 10.3
50 louse-borne relapsing fever 10.3 IL6 MAPK1 TNF

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


snoring, pruritus, fever, coughing

MGI Mouse Phenotypes related to Pertussis:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 TLR4 TNF FOS GNA11 GNAI1 GNAQ
2 homeostasis/metabolism MP:0005376 10.44 JUN MAPK1 MAPK10 OPRM1 TICAM1 TLR4
3 behavior/neurological MP:0005386 10.4 IL10 IL6 JUN MAPK1 MAPK10 FOS
4 immune system MP:0005387 10.37 FOS GNA11 GNAI1 GNAQ IL10 IL1B
5 cardiovascular system MP:0005385 10.35 GNA11 GNAQ IL10 IL1B IL6 ITGB2
6 cellular MP:0005384 10.35 TICAM1 TLR4 TNF JUN MAPK1 MAPK10
7 growth/size/body region MP:0005378 10.35 TNF FOS GNA11 GNAQ GNAZ IL10
8 integument MP:0010771 10.29 TLR4 TNF FOS GNA11 GNAQ GNAZ
9 mortality/aging MP:0010768 10.25 FOS GNA11 GNAQ GNAZ IL10 IL1B
10 nervous system MP:0003631 10.22 FOS GNA11 GNAI1 GNAQ GNAZ IL10
11 endocrine/exocrine gland MP:0005379 10.2 FOS GNA11 GNAQ IL10 IL6 JUN
12 craniofacial MP:0005382 10.1 FOS GNA11 GNAQ IL10 IL1B MAPK1
13 liver/biliary system MP:0005370 10.03 GNA11 IL10 IL6 JUN MAPK1 TICAM1
14 limbs/digits/tail MP:0005371 10 FOS GNA11 GNAQ IL10 TICAM1 TLR4
15 neoplasm MP:0002006 9.97 FOS IL10 IL1B IL6 MAPK1 TICAM1
16 normal MP:0002873 9.91 IL10 ITGB2 JUN OPRM1 TLR4 FOS
17 respiratory system MP:0005388 9.76 GNA11 GNAQ IL10 IL6 JUN MAPK1
18 skeleton MP:0005390 9.73 FOS GNA11 GNAI1 GNAQ IL10 IL1B
19 vision/eye MP:0005391 9.28 FOS IL10 IL6 ITGB2 JUN MAPK1

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
BCG vaccine Investigational Phase 4,Phase 2
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Asthmatic Agents Phase 4
9 Hormone Antagonists Phase 4,Phase 3
10 Hormones Phase 4,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Leukotriene Antagonists Phase 4
13 Respiratory System Agents Phase 4
14 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
16 Protective Agents Phase 4,Phase 3,Phase 2
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
19 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
20 Antacids Phase 4,Phase 3,Phase 2
21 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
23 Antidotes Phase 4,Phase 3,Phase 2
24 Antitoxins Phase 4,Phase 3
25 Diphtheria Antitoxin Phase 4,Phase 3
26 Tetanus Antitoxin Phase 4,Phase 3
27 Anticoagulants Phase 4,Phase 3,Phase 2
28 Calcium, Dietary Phase 4,Phase 3,Phase 2
29 Chelating Agents Phase 4,Phase 3,Phase 2
30 Iron Chelating Agents Phase 4,Phase 3,Phase 2
31 Pentetic Acid Phase 4,Phase 3,Phase 2
32 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
33 PENTA Phase 4,Phase 3,Phase 2
34 Analgesics Phase 4,Phase 3,Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
36 Anti-Inflammatory Agents Phase 4,Phase 3
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Antipyretics Phase 4,Phase 3
39 Antirheumatic Agents Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
42
Deferiprone Approved Phase 3 30652-11-0 2972
43
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
44
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
46
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
47
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
48 gamma-Globulins Phase 3
49 Immunoglobulins, Intravenous Phase 3
50 Rho(D) Immune Globulin Phase 3

Interventional clinical trials:

(show top 50) (show all 462)

# Name Status NCT ID Phase Drugs
1 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
2 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
3 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
5 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
6 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
7 Pertussis and Meningitis C Concomitant Vaccination in Adolescents Completed NCT02526394 Phase 4 Pertussis containing vaccine
8 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
9 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
10 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
11 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
12 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
13 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
14 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
15 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
18 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
19 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
20 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
21 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
22 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
23 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
24 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
25 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
26 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
27 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
28 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
29 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
30 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
31 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
32 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
33 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
34 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
35 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
36 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
37 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
38 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
39 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
40 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
41 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
42 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
43 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
44 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
45 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
46 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
47 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
48 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
49 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
50 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: whooping cough

Genetic Tests for Pertussis

Anatomical Context for Pertussis

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

18
Respiratory Tract

MalaCards organs/tissues related to Pertussis:

38
Testes, T Cells, Monocytes, Neutrophil, Breast, Lung, B Cells

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 1221)
# Title Authors Year
1
Risk factors for pertussis among hospitalized children in a high HIV prevalence setting, South Africa. ( 29410230 )
2018
2
Core pertussis transmission groups in England and Wales: A tale of two eras. ( 29395520 )
2018
3
Cognitive Development One Year After Infantile Critical Pertussis. ( 29394223 )
2018
4
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
5
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
6
A General Lack of IgG Against Pertussis Toxin in Chinese Pregnant Women and Newborns. ( 29406469 )
2018
7
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
8
Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. ( 29411776 )
2018
9
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection. ( 29408190 )
2018
10
Bordetella pertussis (Bp) disease: Before (2003-2011) and after (2013-2016) maternal immunization strategy in a pediatric hospital. ( 29429812 )
2018
11
Response to: Bordetella Pertussis in hajj pilgrims. ( 29449052 )
2018
12
Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3. ( 29433898 )
2018
13
Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles. ( 29416544 )
2018
14
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
15
A rapid lateral flow immunoassay for serological diagnosis of pertussis. ( 29426656 )
2018
16
Maternal Care Providers' Barriers Regarding Influenza and Pertussis Vaccination During Pregnancy in Catalonia, Spain. ( 29417364 )
2018
17
Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. ( 29426663 )
2018
18
Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015. ( 29439872 )
2018
19
Ectopic Expression of O Antigen in<i>Bordetella pertussis</i>by a Novel Genomic Integration System. ( 29404410 )
2018
20
The importance of involving midwives before and during the implementation of an antenatal pertussis vaccination program in New South Wales, Australia. ( 29398459 )
2018
21
Bordetella Pertussis in hajj pilgrims. ( 29395635 )
2018
22
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
23
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
24
Outbreak investigation of pertussis in an elementary school: a case-control study among vaccinated students. ( 29399582 )
2018
25
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
26
Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. ( 29391374 )
2018
27
Identification and characterization of a brilliant yellow pigment produced by Bordetella pertussis. ( 28906022 )
2017
28
Monitoring Pertussis Infections Using Internet Search Queries. ( 28874880 )
2017
29
Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years. ( 28017441 )
2017
30
Resurgence of Pertussis and Emergence of the Ptxp3 Toxin Promoter Allele in South Italy. ( 28945679 )
2017
31
Emerging Bordetella pertussis Strains Induce Enhanced Signaling of Human Pattern Recognition Receptors TLR2, NOD2 and Secretion of IL-10 by Dendritic Cells. ( 28076445 )
2017
32
Pertussis in Poland in 2015 ( 29415525 )
2017
33
The Timing of Pertussis Cases in Unvaccinated Children in an Outbreak Year: Oregon 2012. ( 28088399 )
2017
34
Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832480 )
2017
35
Estimating Pertussis Susceptibility Among 0-23-Month-Old Children in the United States. Using National Immunization Survey (NIS) 2013. ( 28060041 )
2017
36
Ric-8A-mediated stabilization of the trimeric G protein subunit GI+i is inhibited by pertussis toxin-catalyzed ADP-ribosylation. ( 28082199 )
2017
37
Re: Clinical Diagnosis of Bordetella Pertussis Infection: A Systematic Review. ( 28923822 )
2017
38
Assessing the social and environmental determinants of pertussis epidemics in Queensland, Australia: a Bayesian spatio-temporal analysis. ( 28091337 )
2017
39
Retinal haemorrhage in infants with pertussis. ( 28939637 )
2017
40
Pertussis Maternal Immunization: Narrowing the Knowledge Gaps on the Duration of Transferred Protective Immunity and on Vaccination Frequency. ( 28932228 )
2017
41
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832489 )
2017
42
Co-administration of BCG and Diphtheria-tetanus-pertussis (DTP) Vaccinations May Reduce Infant Mortality More Than the WHO-schedule of BCG First and Then DTP. A Re-analysis of Demographic Surveillance Data From Rural Bangladesh. ( 28784413 )
2017
43
Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections. ( 28916245 )
2017
44
Intention to accept pertussis vaccine among pregnant women in Karachi, Pakistan. ( 28863869 )
2017
45
Risk of Pertussis in Relation to Degree of Prematurity in Children < 2 Years of Age. ( 28067717 )
2017
46
Characteristics of Bordetella pertussis infection among infantsand children admitted to paediatric intensive care units in Greece: A multicentre, 11-year study. ( 28058755 )
2017
47
When Escherichia coli doesn't fit the mold: A pertussis-like toxin with altered specificity. ( 28887436 )
2017
48
Immune persistence after pertussis vaccination. ( 28045580 )
2017
49
Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. ( 29107347 )
2017
50
Risk factors for pertussis in adults and teenagers in England. ( 28065204 )
2017

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.22 CALM1 FOS IL10 IL1B IL6 ITGAM
2
Show member pathways
14.07 FOS GNA11 GNA14 GNA15 GNAI1 GNAQ
3
Show member pathways
14.02 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
4
Show member pathways
13.93 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
5
Show member pathways
13.81 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
6
Show member pathways
13.74 CALM1 FOS GNA11 GNA14 GNA15 IL10
7
Show member pathways
13.66 CALM1 GNAI1 GNAQ IL1B IL6 JUN
8
Show member pathways
13.57 CALM1 FOS IL10 IL1B IL6 ITGAM
9
Show member pathways
13.56 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
10
Show member pathways
13.54 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
11
Show member pathways
13.52 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
12
Show member pathways
13.5 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
13
Show member pathways
13.48 FOS IL10 IL1B IL6 JUN MAPK1
14
Show member pathways
13.46 CALM1 FOS GNAI1 IL6 JUN MAPK1
15
Show member pathways
13.44 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
16
Show member pathways
13.32 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ
17
Show member pathways
13.29 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
18
Show member pathways
13.29 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
19
Show member pathways
13.28 FOS GNA11 GNA14 GNA15 GNAI1 IL6
20
Show member pathways
13.26 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
21
Show member pathways
13.24 CALM1 FOS IL6 ITGAM JUN MAPK1
22
Show member pathways
13.23 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
23
Show member pathways
13.21 CALM1 FOS IL1B IL6 JUN MAPK1
24
Show member pathways
13.21 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
25
Show member pathways
13.12 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
26
Show member pathways
13.12 CALM1 FOS GNA11 GNA14 GNA15 GNAI1
27 13.08 CALM1 FOS GNA11 GNAI1 GNAQ IL6
28
Show member pathways
13.07 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
29
Show member pathways
13.03 CALM1 FOS GNA11 GNAI1 ITGAM ITGB2
30
Show member pathways
13.03 FOS IL1B IL6 JUN MAPK1 MAPK10
31
Show member pathways
13.02 IL6 JUN MAPK1 MAPK10 TNF
32
Show member pathways
13.01 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
33
Show member pathways
13 CALM1 GNA11 GNAI1 IL6 MAPK1 MAPK10
34
Show member pathways
12.99 CALM1 FOS GNA11 GNAI1 GNAQ MAPK1
35
Show member pathways
12.96 FOS GNA11 GNA14 GNA15 GNAI1 GNAZ
36 12.95 FOS IL1B JUN MAPK1 MAPK10 TNF
37
Show member pathways
12.95 CALM1 GNAI1 GNAQ ITGAM ITGB2 MAPK1
38
Show member pathways
12.95 CALM1 FOS GNA11 GNAI1 GNAQ JUN
39
Show member pathways
12.92 FOS IL6 JUN MAPK1 TNF
40
Show member pathways
12.91 CALM1 GNA11 GNAI1 GNAQ MAPK1
41
Show member pathways
12.9 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ
42
Show member pathways
12.88 CALM1 FOS GNA15 IL10 JUN MAPK1
43
Show member pathways
12.87 FOS IL1B JUN MAPK1 MAPK10 TNF
44
Show member pathways
12.86 CALM1 FOS JUN MAPK1 MAPK10
45
Show member pathways
12.85 CALM1 IL1B IL6 TLR4 TNF
46
Show member pathways
12.85 FOS IL10 IL1B IL6 JUN MAPK1
47
Show member pathways
12.85 CALM1 FOS GNA11 GNAI1 GNAQ GNAZ
48
Show member pathways
12.84 CALM1 FOS GNA11 GNAQ IL1B JUN
49
Show member pathways
12.83 CALM1 FOS GNA15 GNAI1 GNAQ JUN
50
Show member pathways
12.82 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAZ

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 9.26 FOS JUN
2 heterotrimeric G-protein complex GO:0005834 9.1 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
3 integrin alphaM-beta2 complex GO:0034688 8.96 ITGAM ITGB2
4 extracellular exosome GO:0070062 10.02 CALM1 GNA11 GNA14 GNAI1 GNAQ GNAZ
5 plasma membrane GO:0005886 10 CALM1 GNA11 GNA14 GNA15 GNAI1 GNAQ

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.98 FOS IL10 ITGB2 JUN
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 IL1B TICAM1 TLR4 TNF
3 Fc-epsilon receptor signaling pathway GO:0038095 9.97 CALM1 FOS JUN MAPK1 MAPK10
4 inflammatory response GO:0006954 9.97 FOS IL10 IL1B IL6 ITGB2 TICAM1
5 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 IL6 TICAM1 TLR4 TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 IL1B IL6 ITGB2 TICAM1 TLR4 TNF
7 positive regulation of DNA binding transcription factor activity GO:0051091 9.92 IL10 IL1B IL6 TNF
8 activation of MAPK activity GO:0000187 9.91 IL1B MAPK1 MAPK10 TLR4 TNF
9 apoptotic signaling pathway GO:0097190 9.9 TICAM1 TLR4 TNF
10 positive regulation of JNK cascade GO:0046330 9.9 IL1B TLR4 TNF
11 response to glucocorticoid GO:0051384 9.89 IL10 IL6 TNF
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.88 TICAM1 TLR4 TNF
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 IL6 JUN TNF
14 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.87 GNAI1 GNAZ OPRM1
15 positive regulation of interferon-gamma production GO:0032729 9.84 IL1B TLR4 TNF
16 cellular response to reactive oxygen species GO:0034614 9.82 FOS JUN MAPK1
17 cellular response to cadmium ion GO:0071276 9.8 FOS JUN MAPK1
18 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.8 GNA11 GNA14 GNA15 GNAI1 GNAZ
19 positive regulation of interleukin-8 production GO:0032757 9.79 IL1B TLR4 TNF
20 negative regulation of interleukin-6 production GO:0032715 9.79 IL10 TLR4 TNF
21 regulation of DNA binding transcription factor activity GO:0051090 9.78 FOS JUN MAPK1 MAPK10
22 positive regulation of NF-kappaB import into nucleus GO:0042346 9.77 IL1B TLR4 TNF
23 positive regulation of chemokine production GO:0032722 9.77 IL6 TLR4 TNF
24 toll-like receptor 4 signaling pathway GO:0034142 9.75 ITGAM ITGB2 TLR4
25 amyloid-beta clearance GO:0097242 9.73 ITGAM ITGB2
26 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 GNA11 GNA14 GNA15 GNAQ
27 platelet activation GO:0030168 9.73 GNA11 GNA14 GNA15 GNAQ IL6 MAPK1
28 phototransduction, visible light GO:0007603 9.72 GNA11 GNAQ
29 negative regulation of lipid storage GO:0010888 9.72 IL6 TNF
30 negative regulation of synaptic transmission GO:0050805 9.72 GNAI1 IL1B
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 IL1B TNF
32 positive regulation of interleukin-6 production GO:0032755 9.72 IL1B IL6 TICAM1 TLR4 TNF
33 entrainment of circadian clock GO:0009649 9.71 GNA11 GNAQ
34 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
35 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
36 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TICAM1 TNF
37 regulation of establishment of endothelial barrier GO:1903140 9.69 IL1B TNF
38 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.69 TICAM1 TLR4
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 TLR4
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.68 TICAM1 TLR4
41 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
42 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.67 TICAM1 TLR4
43 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
44 sequestering of triglyceride GO:0030730 9.66 IL1B TNF
45 cellular extravasation GO:0045123 9.65 ITGB2 TNF
46 positive regulation of neutrophil degranulation GO:0043315 9.65 ITGAM ITGB2
47 receptor biosynthetic process GO:0032800 9.64 IL10 TNF
48 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 IL1B TNF
49 regulation of melanocyte differentiation GO:0045634 9.61 GNA11 GNAQ
50 positive regulation of nitric oxide biosynthetic process GO:0045429 9.55 IL1B ITGB2 TICAM1 TLR4 TNF

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.86 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
2 GTP binding GO:0005525 9.85 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
3 cytokine activity GO:0005125 9.8 IL10 IL1B IL6 TNF
4 GTPase activity GO:0003924 9.8 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
5 G-protein coupled receptor binding GO:0001664 9.63 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
6 G-protein coupled serotonin receptor binding GO:0031821 9.48 GNAI1 GNAZ
7 complement component C3b binding GO:0001851 9.46 ITGAM ITGB2
8 G-protein beta/gamma-subunit complex binding GO:0031683 9.43 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
9 type 2A serotonin receptor binding GO:0031826 9.4 GNA11 GNAQ
10 guanyl nucleotide binding GO:0019001 9.1 GNA11 GNA14 GNA15 GNAI1 GNAQ GNAZ
11 protein binding GO:0005515 10.39 CALM1 FOS GNA14 GNAI1 GNAQ GNAZ

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....